Overview

Osimertinib In EGFR Mutant Lung Cancer

Status:
Recruiting

Trial end date:
2024-03-01

Target enrollment:

Participant gender:

Summary

This research study is studying a targeted therapy as a possible treatment for Non-Small Cell Lung Cancer (NSCLC) with an EGFR mutation. The names of the study drug involved in this study is: - Osimertinib (Tagrisso)

Phase:

Phase 2

Details

Lead Sponsor:

Dana-Farber Cancer Institute

Collaborator:

AstraZeneca

Treatments:

Osimertinib